Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relative Bioavailability of BI 894416 as Tablet Formulation Following a High-fat, High-calorie Breakfast Compared to Administration in the Fasting State in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)

NCT03871595 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03871595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03871595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relative Bioavailability of BI 894416 as Tablet Formulation Following a High-fat, High-calorie Breakfast Compared to Administration in the Fasting State in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
March 20, 2019
Completion date
April 24, 2019
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy